Genomic strategies to improve outcome and individualize therapy in cancer: The paradigm of childhood acute lymphoblastic leukemia

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Kager, Leo ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Acute lymphoblastic leukemia; Cancer; Drug therapy; Genomic variants; Outcome; Pharmacogenomics

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; GLUCOCORTICOID; INTERLEUKIN 15; LESTAURTINIB; MERCAPTOPURINE; METHOTREXATE; MIDOSTAURIN; RAPAMYCIN; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; FEBRILE NEUTROPENIA; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; LIVER VENOOCCLUSIVE DISEASE; NONHUMAN; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHILD; GENETIC ASSOCIATION STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; METHOTREXATE; PHARMACOGENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 70350044042     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
2. Meijerink JP, den Boer M L, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 16-23.
3. Pieters R, Schrappe M, De Lorenzo P et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250. (Pubitemid 47082422)
4. Attarbaschi A, Mann G, Panzer-Grumayer R et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 2008; 26: 3046-3050.
5. Mullighan CG, Su X, Zhang J et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
6. Den Boer ML, van Slegtenhorst M, De Menezes RX et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
7. Coustan-Smith E, Mullighan CG, Onciu M et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
8. Kager L, Lion T, Attarbaschi A et al. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica 2007; 92: 1561-1564. (Pubitemid 350144133)
9. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464-468.
10. Kager L, Evans WE. Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol 2006; 13: 260-265.
11. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117-129.
12. Cheok MH, Pottier N, Kager L, Evans WE. Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 39-51.
13. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
14. Kager L, Evans, WE. Pharmacogenomics in Hematologic Diseases. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H (Eds): Hematology. Basic Principles and Practice (5th Edn). Elsevier, 2008, pp 93-106.
15. Huang RS, Retain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59: 42-55.
16. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009; 46: 52-63.
17. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25: 1629-1638.
18. Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005;293:1485-1489. (Pubitemid 40393293)
19. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
20. Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 2006; 80: 375-383. (Pubitemid 44479753)
21. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107: 843-844. (Pubitemid 43076417)
22. Schaeffeler E, Fischer C, Brockmeier D et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-417. (Pubitemid 38971231)
23. Stocco G, Cheok MH, Crews KR et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85: 164-172.
24. Kager L, Cheok M, Yang W et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115: 110-117. (Pubitemid 40385511)
25. Sorich MJ, Pottier N, Pei D et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 2008; 5: e83.
26. Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 2006; 80: 468-476. (Pubitemid 44737489)
27. Yang JJ, Cheng C, Yang W et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393-403.
28. Aplenc R, Thompson J, Han P et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482-2487. (Pubitemid 40490161)
29. Gadner H, Masera G, Schrappe M et al. The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ("Ponte di legno meeting") report: Vienna, Austria, April 27-28, 2005. Leukemia 2006; 20: 9-17. (Pubitemid 36519380)
30. French D, Yang W, Cheng C et al. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 2008; 113: 4512-4520.
31. Holleman A, Cheok MH, den Boer ML et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351: 533-542. (Pubitemid 39025170)
32. Lugthart S, Cheok MH, den Boer ML et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005; 7: 375-386. (Pubitemid 40544654)
33. Lamb J, Crawford ED, Peck D et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935. (Pubitemid 44497995)
34. Wei G, Twomey D, Lamb J et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-342. (Pubitemid 44512194)
35. Cheok MH, Yang W, Pui CH et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003; 34: 85-90. (Pubitemid 36548796)
36. Yeoh EJ, Ross ME, Shurtleff SA et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
37. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105: 812-820. (Pubitemid 40070769)
38. Stam RW, den Boer ML, Schneider P et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106: 2484-2490. (Pubitemid 41510823)
39. Cario G, Izraeli S, Teichert A et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol 2007; 25: 4813-4820. (Pubitemid 350086486)